Overview

DNAPrint genomics Inc. is developing products to provide the tools and information needed for personalized medicine. The company uses high-throughput genetic analysis on both chip-based and electrophoresis-based platforms combined with software tools to facilitate understanding of how genotypes result in phenotypes such as eye color and reactivity to medications in a field called Phenomics, or the study of genomic information to understand the relationship between genotype and phenotype. The company has compiled unique SNP and haplotype maps of the human genome as a starting point for using population genetics in developing medical products. In October 2001, the company marketed its first commercial product a genetic basis for predicting eye color for use in the human forensics market.

Partners

The company has partnerships with the University of Miami to identify genetic variations responsible for differing responses to chemotherapeutic agents used in ovarian cancer, and with New York University School of Medicine to develop pharmacogenomic classifiers for organ transplant patients. It also works with Orchid Biosciences to develop and commercialize DNAPrint technologies and has collaborations with independent groups of physicians in both Jacksonville, Fla., and Naples, Fla.